Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eftilagimod alfa + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Immutep
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Eftilagimod alfa + pembrolizumab is an investigational combination immunotherapy regimen for cancer. Eftilagimod alfa (efti) is a soluble LAG-3 protein that acts as an MHC class II agonist to activate antigen-presenting cells and enhance T cell responses. Pembrolizumab is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 and thereby promoting anti-tumor immune activity. The combination aims to provide complementary activation of the immune system by stimulating both innate and adaptive immunity. This regimen has shown promising efficacy in clinical trials for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), metastatic non–small cell lung cancer (NSCLC), and soft tissue sarcoma[2][3][4][5][6].
- Other names
- MK-3475MK3475MK 3475eftiIMP321IMP-321IMP 321
02
Targets
MHC II (Major histocompatibility complex class II receptor)PDCD1 (Programmed cell death protein 1 receptor)LAG3 (Lymphocyte activation Gene-3 protein)
Beyond the preview
Go deeper on eftilagimod alfa + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eftilagimod alfa + pembrolizumab.